Reactivation of Plasmodium infection during a treatment with infliximab: A case report

Haeseleer, Cécile; Martiny, Delphine; Laethem, Y. Van; Cantinieaux, Brigitte; Martin, Charlotte

doi:10.1016/j.ijid.2019.11.016

Cited by 9 publications

(6 citation statements)

References 13 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The causative agents for malaria infections are Plasmodium protozoans (i.e. Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax), although most severe infections are caused by P. falciparum [2][3][4]. Most deaths are recorded among African children below the age of 5 years [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

“…Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax), although most severe infections are caused by P. falciparum [2][3][4]. Most deaths are recorded among African children below the age of 5 years [1][2][3][4]. This calls for an urgent need for new anti-malarial therapies for any one of the following reasons:…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019

Bekono

Ntie‐Kang

Onguéné

et al. 2020

Malar J

View full text Add to dashboard Cite

Background African Traditional Medicine (ATM) is used for the healthcare of about 80% of the rural populations of the continent of Africa. The practices of ATM make use of plant-products, which are known to contain plant-based secondary metabolites or natural products (NPs), likely to play key roles in drug discovery, particularly as lead compounds. For various reasons, including resistance of strains of Plasmodium to known anti-malarial drugs, local African populations often resort to plant-based treatments and/or a combination of this and standard anti-malarial regimens. Emphasis has been laid in this review to present the anti-malarial virtue of the most recently published phytochemicals or natural products, which have been tested by in vitro and in vivo assays. Methods The data was based on the current version of the African Compound Libraries, which are constantly being updated based on inputs from journal articles and student theses (M.Sc/Ph.D) from African University libraries. Emphasis was laid on data published after 2012. In order to carry out the original data collection, currently being included in the African Compounds Database, individual journal websites were queried using the country names in Africa as search terms. Over 40,000 articles “hits” were originally retrieved, then reduced to about 9000 articles. The retained articles/theses was further queried with the search terms “malaria”, “malarial”, “plasmodium”, “plasmodial” and a combination of them, resulting in over 500 articles. Those including compounds with anti-malarial activities for which the measured activities fell within the established cut off values numbered 55, which were all cited in the review as relevant references. Results and discussion Pure compounds derived from African medicinal plants with demonstrated anti-malarial/antiplasmodial properties with activities ranging from “very active” to “weakly active” have been discussed. The majority of the 187 natural products were terpenoids (30%), followed by flavonoids (22%), alkaloids (19%) and quinones (15%), with each of the other compound classes being less than 5% of the entire compound collection. It was also observed that most of the plant species from which the compounds were identified were of the families Rubiaceae, Meliaceae and Asphodelaceae. The review is intended to continue laying the groundwork for an African-based anti-malarial drug discovery project.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019

Bekono

Ntie‐Kang

Onguéné

et al. 2020

Malar J

View full text Add to dashboard Cite

show abstract

“…Malaria parasites in asymptomatic carriers act as a silent reservoir that needs to be identified and targeted for elimination as global warming could lead to climate conditions favorable to vector-borne diseases such as malaria, and there is also a risk of reactivation in immunosuppressed patients. 22 Detection of malaria in semi-immune asymptomatic migrants by PCR has shown to be more sensitive than the usual tests used for screening, detecting twice as many infections as OptiMAL Rapid Detection Tests and 25% more than microscopy. 23,24 The CDC recommends that refugees originating from sub-Saharan Africa who have not received predeparture treatment with a recommended regimen receive presumptive treatment upon arrival or undergo laboratory testing to detect Plasmodium infection.…”

Section: Discussionmentioning

confidence: 99%

Health and Vaccination Status of Unaccompanied Minors After Arrival in a European Border Country: A Cross-sectional Study (2017–2020)

Carreras-Abad

Oliveira-Souto

Pou-Ciruelo

et al. 2022

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Unaccompanied and separated children (UASC) are a high-risk group for infectious diseases and information on their vaccination status is scarce. Different approaches are used to screen newly arrived minors in Europe. The aim of this study was to describe the health status and serological protection against different vaccine-preventable diseases among UASC to inform public health decision-making. Methods: Retrospective study of all UASC seen at an international health reference center in Barcelona (Spain) between January 2017 and February 2020. Screening results were analyzed using binary logistic regression with adjustment for symptoms, geographic origin, and time since arrival. Results: We studied 289 UASC (88.9% males; median age, 17 years). At least one infection was diagnosed in 136 minors (47.1%). There was a high prevalence of intestinal parasites (22.8%), latent tuberculosis infection (22.5%), and hepatitis B (5.2%), even in asymptomatic individuals, and especially among UASC from sub-Saharan Africa (odds ratio, 2.5; 95% confidence interval, 1.5–4.0, P < 0.001). We did not observe a significant association between clinical symptoms and the presence of infection or differences in the prevalence of different infections according to number of months since arrival. Protection against hepatitis B virus (36%), measles (80%), and varicella (83%) was suboptimal. Conclusions: Our results highlight the importance of screening and vaccination programs for UASC arriving in Europe, especially border countries. Protocols should be adjusted according to geographic origin. Absence of symptoms does not necessarily rule out infection, highlighting the importance of screening in asymptomatic minors. These programs are a public health priority and should not be neglected during the current COVID-19 pandemic.

show abstract

“…Several conditions impairing immunity, such as pregnancy, cancer and HIV infection, probably represent additional risk factors for recrudescence [5,16]. Notably, two cases of P. falciparum malaria late reactivation have been described in patients treated with biological agents (namely, infliximab and tocilizumab) for inflammatory disorders [17,18]; this is consistent with previous evidence showing the relevant role of tumor necrosis factor α (TNF α) and interleukin 6 (IL-6) in promoting parasite clearance [15]. Finally, P. falciparum recrudescences in patients undergoing splenectomy for suspected lymphoma were reported, further supporting the hypothesis that immune suppression, either iatrogenic or due to acquired diseases, may trigger malaria reactivation in people with low-level parasitaemia [19].…”

Section: N Discussionmentioning

confidence: 99%

Recrudescence of Plasmodium falciparum malaria 5 years after treatment in an HIV migrant: a case report with a peculiar presentation

et al. 2022

View full text Add to dashboard Cite

In the last two decades, several cases of delayed-onset malaria in migrants from endemic areas were reported. The decrease of acquired immunity over time, often enhanced by immune suppression, represents a possible underlying mechanism for recrudescence. Here we describe a case of Plasmodium falciparum malaria occurring five years after exposure in a patient infected with human immunodeficiency virus, originating from Ivory Coast. Peculiarly, bilateral subsegmental pulmonary SUMMARY embolism in the absence of deep venous thrombosis was also detected, requiring anticoagulant therapy. Treatment with dihydroartemisinin/piperaquine was followed by clearance of trophozoites and the patient was discharged home.

show abstract

Reactivation of Plasmodium infection during a treatment with infliximab: A case report

Abstract: A B S T R A C TWe describe a symptomatic Plasmodium falciparum infection in a 29-year-old Guinean man receiving Infliximab for one year and without recent travel. The reactivation of submicroscopic malaria following the inhibition of TNF-alpha by infliximab is suspected.

Cited by 9 publications

References 13 publications

The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019

The potential of anti-malarial compounds derived from African medicinal plants: a review of pharmacological evaluations from 2013 to 2019

Health and Vaccination Status of Unaccompanied Minors After Arrival in a European Border Country: A Cross-sectional Study (2017–2020)

Recrudescence of Plasmodium falciparum malaria 5 years after treatment in an HIV migrant: a case report with a peculiar presentation

Contact Info

Product

Resources

About